文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

TLR与IFNα/β协同信号使IL-18表达逃逸内毒素耐受

Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01
一句话结论人单核细胞IL-18(而非IL-1β)产生需要Toll样受体与IFNα/β信号协同,JAK/STAT抑制可降低复发性MAS患者血清IL-18水平。

该研究探讨人IL-18表达调控机制,利用体内外内毒素再攻击实验、炎症疾病患者样本及多种刺激和药物处理的人单核细胞,检测细胞因子基因和蛋白表达;并在两种MAS小鼠模型和一名复发性MAS患者中分析JAK/STAT抑制对血清IL-18的影响。结果显示外周血和单核细胞IL-18表达逃逸LPS诱导的免疫麻痹,LPS刺激的原代人单核细胞IL-18表达动力学受IFNα/β信号控制,JAK/STAT抑制或IFNβ中和可减弱细胞因子表达;微管解聚药物消除LPS诱导的IL18表达,但可被IFNα/β完全逆转。炎症疾病患者全血中I型IFN评分与IL18表达强相关,JAK/STAT抑制在两种MAS小鼠模型和一名复发性MAS患者中强烈降低血清IL-18水平。结论提示干扰IFNα/β表达或JAK/STAT抑制后信号可能控制MAS中的灾难性过度炎症。

要点

  • 人单核细胞IL-18(而非IL-1β)产生需要Toll样受体与IFNα/β信号协同。
  • 外周血和单核细胞IL-18表达逃逸LPS诱导的免疫麻痹。
  • LPS刺激的原代人单核细胞中,JAK/STAT抑制或IFNβ中和可减弱IL-18表达。
  • 微管解聚药物消除LPS诱导的IL18表达,但可被IFNα/β完全逆转。
  • JAK/STAT抑制在两种MAS小鼠模型和一名复发性MAS患者中强烈降低血清IL-18水平。

适用人群与场景

  • 体外实验使用原代人单核细胞;体内外内毒素再攻击实验样本;炎症疾病患者全血;两种MAS小鼠模型;一名复发性MAS患者。

处置流程与药物剂量

  • 在LPS刺激的原代人单核细胞中,JAK/STAT抑制或IFNβ中和可减弱IL-18表达。
  • 微管解聚药物可消除LPS诱导的IL18表达,但加入IFNα/β可完全逆转该效应。
  • 在两种MAS小鼠模型和一名复发性MAS患者中,JAK/STAT抑制强烈降低血清IL-18水平。

研究设计与关键结果

  • 研究类型为实验研究(体内外内毒素再攻击实验、原代人单核细胞实验、MAS小鼠模型及病例观察),样本量原文未报告。
  • 外周血和单核细胞IL-18表达逃逸LPS诱导的免疫麻痹。
  • LPS刺激的原代人单核细胞显示受IFNα/β信号控制的特定IL-18表达动力学。
  • 炎症疾病患者全血中I型IFN评分与IL18表达强相关。
  • JAK/STAT抑制在两种MAS小鼠模型和一名复发性MAS患者中强烈降低血清IL-18水平。

证据类型、等级与局限

  • 证据类型为实验研究(含体外细胞实验、动物模型及病例观察),原文未给出证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,干扰IFNα/β表达或JAK/STAT抑制后信号可能控制MAS中的灾难性过度炎症。
  • 原文未据此给出急诊或ICU临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: IL-18 is a member of the IL-1 cytokine family, and elevated blood IL-18 concentrations associate with disease activity in macrophage activation syndrome (MAS) and poor clinical outcomes in severe inflammatory and septic conditions.Objectives: Although recent investigations provide mechanistic evidence for a contribution of IL-18 to inflammation and hyperinflammation in sepsis and MAS, we sought to study regulatory mechanisms underlying human IL-18 expression.Methods: Samples from in vivo and in vitro endotoxin rechallenge experiments, patients with inflammatory disease, and isolated human monocytes treated with various stimulants and drugs were tested for cytokine gene and protein expression. Serum IL-18 expression with or without JAK/STAT inhibition was analyzed in two MAS mouse models and in a patient with recurrent MAS.Measurements and Main Results: Peripheral blood and monocytic IL-18 expression escaped LPS-induced immunoparalysis. LPS-stimulated primary human monocytes revealed specific IL-18 expression kinetics controlled by IFNα/β signaling. JAK/STAT inhibition or IFNβ neutralization during LPS stimulation blunted cytokine expression. Similarly, microtubule-destabilizing drugs abrogated LPS-induced IL18 expression, but this effect could be fully reversed by addition of IFNα/β. Ex vivo analysis of inflammatory disease patients' whole blood revealed strong correlation of type I IFN score and IL18 expression, whereas JAK/STAT inhibition strongly reduced IL-18 serum levels in two MAS mouse models and in a patient with recurrent MAS.Conclusions: Our data indicate that IL-18 (but not IL-1β) production from human monocytes requires cooperative Toll-like receptor and IFNα/β signaling. Interference with IFNα/β expression or signaling following JAK/STAT inhibition may control catastrophic hyperinflammation in MAS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Verweyen E, Holzinger D, Weinhage T, et al. Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. Am J Respir Crit Care Med. 2020. PMID: 31710506. doi:10.1164/rccm.201903-0659OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。